Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376
Phase 1 Unknown
75 enrolled
WinPro
Phase 2 Unknown
200 enrolled
HOT
Phase 3 Unknown
1,884 enrolled
NEMO
Unknown
300 enrolled
HOBOE
Phase 3 Unknown
1,294 enrolled
ASPAIT
Phase 3 Unknown
680 enrolled
A Study of TY-302 in Patients With Advanced Solid Tumors
Phase 1 Unknown
60 enrolled
CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
Phase NA Unknown
150 enrolled
Therapeutic Dose Monitoring (TDM) of Tamoxifen
Phase 2 Unknown
40 enrolled
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
Unknown
1,000 enrolled
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
Unknown
1,354 enrolled
NUTRIBREAST
Unknown
300 enrolled
Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors
Phase 3 Unknown
412 enrolled
Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery
Phase 3 Unknown
3,697 enrolled
Sleep and Activity Patterns in Pre-menopausal Breast Cancer Patients on Tamoxifen Using a Wrist-worn Internet of Things Device
Unknown
20 enrolled
MEGA
Phase 2 Unknown
20 enrolled
Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer
Phase 2 Unknown
185 enrolled
Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen
Unknown
100 enrolled
STEP
Phase 3 Unknown
300 enrolled
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
Phase 2/3 Unknown
200 enrolled
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
Phase 3 Unknown
844 enrolled
OTT 17-01
Phase 2 Unknown
82 enrolled
Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
Phase 3 Unknown
600 enrolled
Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients
Phase NA Unknown
600 enrolled
Decision Aids for Tamoxifen Treatment in Breast Cancer Patients
Phase NA Unknown
360 enrolled
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer
Phase 3 Unknown
4,400 enrolled
Tamoxifen in Treating Women With Breast Cancer
Phase 3 Unknown
20,000 enrolled
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
Phase 3 Unknown
Combination Chemotherapy in Treating Women With Breast Cancer
Phase 3 Unknown
350 enrolled
Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer
Phase 3 Unknown
300 enrolled
Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast
Phase NA Unknown
100 enrolled
NEST
Phase 3 Unknown
290 enrolled
Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
Phase 3 Unknown
Comparison of Four Different Treatment Regimens in Treating Women With Stage I Breast Cancer
Phase 3 Unknown
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
Phase 3 Unknown
2,500 enrolled
Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer
Phase NA Unknown
2,000 enrolled
CONSET
Phase 3 Unknown
260 enrolled
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
Phase 2 Unknown
94 enrolled
ASTRRA-CYP2D6
Unknown
922 enrolled
ASTRRA
Phase 3 Unknown
1,234 enrolled
Combination Chemotherapy in Treating Women With Resected Breast Cancer
Phase 2 Unknown
Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole
Phase 2 Unknown
2,000 enrolled